Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity
暂无分享,去创建一个
A. Luini | A. Goldhirsch | G. Viale | M. Intra | P. Maisonneuve | M. Colleoni | P. Veronesi | N. Rotmensz | E. Montagna | A. Cardillo | L. Bottiglieri | R. Torrisi | E. Campagnoli
[1] F. Hirsch,et al. Epidermal growth factor receptor immunohistochemistry , 2008, Cancer.
[2] Samuel Leung,et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.
[3] B. Calvo,et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Luini,et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. , 2007, European journal of cancer.
[5] A. Luini,et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] E. Shpall,et al. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[8] A. Goldhirsch,et al. New criteria for selecting elderly patients for breast cancer adjuvant treatment studies. , 2007, The oncologist.
[9] R. Gelber,et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Wolfgang Heller,et al. Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.
[11] K. Siziopikou,et al. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. , 2007, Breast.
[12] M. Fernö,et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers , 2007, Breast Cancer Research.
[13] T. Nielsen,et al. Deconstructing the molecular portrait of basal-like breast cancer. , 2006, Trends in molecular medicine.
[14] K. Jirström,et al. High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients , 2006, Clinical Cancer Research.
[15] D. Easton,et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.
[16] A. Ashworth,et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy , 2006, Journal of Clinical Pathology.
[17] Y. Ko,et al. Expression of epidermal growth factor receptor in primary colorectal adenocarcinoma predicts expression in recurrent disease. , 2006, American journal of clinical pathology.
[18] C. Perou,et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.
[19] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[20] A. Vincent-Salomon,et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome , 2005, Modern Pathology.
[21] L. Ramalho,et al. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer , 2005, Histopathology.
[22] G. Ball,et al. High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.
[23] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[24] G. Severi,et al. Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] E. G. Deza,et al. 'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity? , 2005, Breast.
[26] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[27] I. Ellis,et al. Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.
[28] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Umberto Veronesi,et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.
[30] R. Tibshirani,et al. Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .
[31] M. Bonetti,et al. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF , 2002, British Journal of Cancer.
[32] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[33] E. van Marck,et al. Early distant relapse in ‘node‐negative’ breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour , 2001, The Journal of pathology.
[34] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[35] S. Hirohashi,et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. , 2000, The American journal of surgical pathology.
[36] A. Goldhirsch,et al. Prediction of response to primary chemotherapy for operable breast cancer. , 1999, European journal of cancer.
[37] D. Tu,et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Umberto Veronesi,et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes , 1997, The Lancet.
[39] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[40] Anna L. Brown,et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] I Iu IUDIN,et al. [Tumors of the mammary gland]. , 1955, Meditsinskaia sestra.
[42] Ian O Ellis,et al. Prognostic markers in triple‐negative breast cancer , 2007, Cancer.
[43] Ian O Ellis,et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis , 2005, Modern Pathology.
[44] R. Love. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.